Alrehaili Mohammad, Phillips William J, Asmis Tim, Vickers Michael, Marginean Horia, Goodwin Rachel
University of Ottawa Division of Medical Oncology, Ottawa, Ontario, Canada.
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.
Oncology. 2025;103(5):421-426. doi: 10.1159/000540907. Epub 2024 Sep 25.
The incidence of neuroendocrine tumors (NETs) is rising. Our objective was to assess trends in gastroenteropancreatic (GEP)-NETs diagnosis (June 2010 to June 2021) at TOHCC and to explore whether early COVID-19 pandemic data impacted these trends.
This was a single-center retrospective chart review of data collected from June 2010 to June 2021. We searched all databases, including OACIS/EPIC, PACS, and OPIS and found 647 GEP-NET patients. Descriptive analyses were performed using frequencies and related percentages.
Of 647 patients with GEP-NETs, the small bowel was the most common primary location (n = 210, 32.4%), followed by the pancreas (n = 118, 18.2%), and unknown primary location (n = 99, 15.3%). Most of the cases were classified as metastatic or locally advanced at the initial presentation. There has been no significant variation in the frequency distribution of these cases over the last decade. Stages 1 and 2 were found in 158 cases (23.8%), and lower gastrointestinal (GI) tumors were the most common disease among them (n = 88, 55.7%). There were 5 lower GI cases in 2010-2011 and average number per registration year was 5.5 until 2016-2017, after which time the number of cases increased to 10, 15, 11, and 13 during the last 4 years. Regarding early-stage pancreatic and upper GI NETs, the total number of cases was 52 (32.9%) and 18 (11.4%), respectively. The average number of cases per registration year for pancreatic tumors was 4.7, while that for upper GI tumors was 1.6 over the last decade.
At our center, most GEP-NETs presented in an advanced setting. Small bowel is the most common location overall. The incidence of early-stage disease has increased. Disease detection for all GEP-NETs was consistent throughout the last decade, except for the lower GI cases that have increased since mid-2017, perhaps reflecting the adoption of Ontario FIT testing. Despite endoscopy closures and disruption of some diagnostic services during the pandemic, cases of GEP-NETs for all stages did not decrease.
神经内分泌肿瘤（NETs）的发病率正在上升。我们的目标是评估多伦多综合癌症中心（TOHCC）胃肠胰（GEP）-NETs的诊断趋势（2010年6月至2021年6月），并探讨早期新冠疫情数据是否影响了这些趋势。
这是一项对2010年6月至2021年6月收集的数据进行的单中心回顾性图表审查。我们搜索了所有数据库，包括OACIS/EPIC、PACS和OPIS，共发现647例GEP-NET患者。使用频率和相关百分比进行描述性分析。
在647例GEP-NET患者中，小肠是最常见的原发部位（n = 210，32.4%），其次是胰腺（n = 118，18.2%），原发部位不明的有99例（15.3%）。大多数病例在初次就诊时被分类为转移性或局部晚期。在过去十年中，这些病例的频率分布没有显著变化。1期和2期病例有158例（23.8%），其中下消化道（GI）肿瘤是最常见的疾病（n = 88，55.7%）。2010 - 2011年有5例下消化道病例，到2016 - 2017年每个登记年份的平均病例数为5.5例，此后在过去4年中病例数增加到10例、15例、11例和13例。关于早期胰腺和上消化道NETs，病例总数分别为52例（32.9%）和18例（11.4%）。在过去十年中，胰腺肿瘤每个登记年份的平均病例数为4.7例，而上消化道肿瘤为1.6例。
在我们中心，大多数GEP-NETs在晚期出现。小肠是总体上最常见的部位。早期疾病的发病率有所增加。在过去十年中，所有GEP-NETs的疾病检测情况一致，除了自2017年年中以来增加的下消化道病例，这可能反映了安大略省粪便免疫化学检测（FIT）的采用。尽管在疫情期间内镜检查关闭且一些诊断服务中断，但所有阶段的GEP-NETs病例并未减少。
